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Abstract
The live attenuated yellow fever vaccine (YF-17D) has been successfully used for more
than 70 years. It is generally considered a safe vaccine, however, recent reports of serious
adverse events following vaccination have raised concerns and led to suggestions that
even safer YF vaccines should be developed. Replication deficient adenoviruses (Ad) have
been widely evaluated as recombinant vectors, particularly in the context of prophylactic
vaccination against viral infections in which induction of CD8+ T-cell mediated immunity is
crucial, but potent antibody responses may also be elicited using these vectors. In this
study, we present two adenobased vectors targeting non-structural and structural YF anti-
gens and characterize their immunological properties. We report that a single immunization
with an Ad-vector encoding the non-structural protein 3 from YF-17D could elicit a strong
CD8+ T-cell response, which afforded a high degree of protection from subsequent intracra-
nial challenge of vaccinated mice. However, full protection was only observed using a vec-
tor encoding the structural proteins from YF-17D. This vector elicited virus-specific CD8+ T
cells as well as neutralizing antibodies, and both components were shown to be important
for protection thus mimicking the situation recently uncovered in YF-17D vaccinated mice.
Considering that Ad-vectors are very safe, easy to produce and highly immunogenic in
humans, our data indicate that a replication deficient adenovector-based YF vaccine may
represent a safe and efficient alternative to the classical live attenuated YF vaccine and
should be further tested.
Author Summary
Live attenuated yellow fever vaccine (YF-17D) is an efficient and generally safe vaccine.
Nevertheless, in recent years the reporting of serious adverse effects together with the
given limitations in the use of this live vaccine in certain risk groups has spurred an inter-
est in developing a more generally applicable and safer alternative. Using an adenovector
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platform and recombinant vaccines targeting both structural and non-structural YF anti-
gens, we now demonstrate that non-replicating adenobased vaccines may be used to
induce a state of host immunity, which like YF-17D vaccination encompasses both major
arms of the adaptive immune system. Furthermore, in a murine challenge model, adeno-
vector induced protection fully matched that induced by the current vaccine. Taken
together our results strongly suggest that adenovectored vaccines targeting structural and
non-structural viral antigens represent a viable and safe alternative to the existing live,
attenuated YF vaccine.
Introduction
The design of vaccines against viral infections has evolved considerably with the advances in
molecular biology, which have created many alternative approaches to the empirical develop-
ment of live vaccines. Thus, the first generation of live attenuated vaccines and the second gen-
eration of subunit vaccines have now been followed by a third generation of vaccines based
on recombinant DNA technology. The newly designed vaccines have several advantages com-
pared to empiric attenuated live vaccines: their production is faster, cheaper and easier to con-
trol, and, importantly, their safety profile is considerably better than that of live viruses making
them more appealing for use in humans. However, they have rarely shown the same immuno-
genicity as their live predecessors, and the biological mechanisms behind this difference have
been the subject of extensive research.
The yellow fever (YF) vaccine, based on the live attenuated YF-17D virus, was developed in
the 1930s by serial tissue culture passage of wild type YF virus (YFV) in mouse and chicken cell
cultures [1–3]. A single vaccination with YF-17D can confer protection in more than 95% of
the vaccinees, and immunity has been shown to last up to 40 years post vaccination and to cor-
relate with presence of neutralizing Abs [4,5]. In spite of the clear success in preventing infec-
tion with YFV in many areas of the world, the YF-17D vaccine also has its dark side; rare, but
often fatal vaccine-associated adverse events (SAEs) may be induced [5]. These SAEs mainly
fall into two categories: vaccine-associated neurotropic disease (YEL-AND), which consists in
a post-vaccinal encephalitis [5,6], and vaccine-associated viscerotropic disease (YEL-AVD),
which is a pansystemic infection characterized by liver damage, similarly to infection with wild
type YFV [7–9]. Interestingly, sequence analysis of the few isolates obtained from patients in
whom adverse events following vaccination were fatal, demonstrated that the virus had not
reverted to virulence, rather host genetic factors appeared to be responsible for the severe reac-
tion to YF-17D virus [5,10]. Moreover, due to its live viral nature, the YF vaccine is contraindi-
cated in pregnant women, infants, elderly, immunosuppressed and certain HIV infected
individuals as well as in people with hypersensitivity to eggs in which the vaccine is still manu-
factured [5]. In this perspective, implementation of alternative vaccine strategies such as DNA-
based vaccines has become desirable.
Recombinant DNA vaccines in which the antigen is encoded by an attenuated viral vector
have demonstrated great potential, and very recently it has been found that a DNA vaccine
encoding the envelope antigen of YFV may induce protection in murine studies [11]. However,
the immunogenecity of naked DNA vaccines is substantially surpassed by that of replication
deficient adenoviral vectors, which have been found to represent very efficient immunogens
also in primates [12,13]. Thus, vaccination with recombinant adenovectors has been shown to
elicit strong cellular immunity against antigens from several different viral pathogens such as
Ebola virus, lymphocytic choriomeningitis virus, HIV, hepatitis C virus [14–19], as well as
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non-viral pathogens such as Listeria monocytogenes [20] and malaria [21]. In relation to YFV
infection, recent results from our group strongly suggest that long-term clinical protection is
mediated not only by neutralizing antibodies as previously believed [4], but also by virus-spe-
cific CD8+ T cells [22]. Therefore, with the dual purpose of using adenoviral vectors for further
studies of immunity to YFV infection in our intracranial challenge mouse model and to explore
the possibility of developing an adenobased vaccine alternative, we generated two vector con-
structs: an Ad serotype 5 (Ad5) vaccine vector encoding the YF-17D structural proteins core
(C), membrane (M) and envelope (E), as well as an Ad5 vector encoding the viral non-struc-
tural protein 3 (NS3). The rationale behind this strategy was that the former vector would likely
induce a humoral response towards the encoded YF-17D surface antigens, while the latter vec-
tor would induce cell-mediated immunity toward antigens present within YFV infected cells.
Our results showed that vaccination with Ad-YF C,M,E or Ad-YF NS3 both resulted in long-
standing protection of mice from severe YFV infection. While virus-specific CD8+ T cells
appear to represent the major effectors when the viral NS3 protein was chosen as antigen, a
combination of T-cell and B-cell immunity determined the outcome in mice vaccinated with
the vector encoding the three viral structural proteins. Thus, besides strengthening the evidence
for a role of CD8+ T cells in protection against severe YFV infection, our findings point to ade-
noviral vectors as potential vaccine candidates that may be used to develop a safer alternative
for immunization against YFV infection.
Materials and Methods
Mice
Female C57BL/6 (wt B6) mice, B-cell (μMT/μMT) deficient mice, β2-microglobulin (β2m
-/-)
and MHC class II (Aβ
-/-) deficient mice, as well as mice deficient in H-2Kb or in both H-2Kb/
H-2Db molecules, were all obtained from Taconic Farms. Perforin (Prf) deficient and IFN-γ
deficient mice were originally obtained from The Jackson Laboratory and IFN-γ/perforin dou-
ble-deficient (IFN-γ/Prf) mice were generated locally through intercrossing of these strains, as
previously described [23]. All mice used in this study were 7–10 weeks old and housed in a
pathogen–free facility. All experiments were approved by the national animal ethics committee
and performed in accordance to the national guidelines.
Ethics statement
Experiments were conducted in accordance with national Danish guidelines (Amendment #
1306 of November 23, 2007) regarding animal experiments as approved by the Danish Animal
Experiments Inspectorate, Ministry of Justice, permission number 2009/561-1679. The mice
were housed in accordance with good animal practice as defined by FELASA.
Recombinant adenoviral vectors
pacCMV shuttle vectors encoding the structural proteins core, membrane and envelope (C, M,
E), and the nonstructural protein 3 (NS3) from YF-17D virus (GenBank: X03700.1) were
obtained from GenScript (Piscataway, NJ, USA). pacCMV vectors encoding the truncated
form of NS3 (aa. 201–325) were also obtained from Gen Script (Piscataway, NJ, USA).
From all shuttle plasmids, human type 5 recombinant adenovirus (Ad5) vectors were pro-
duced through homologous recombination by standard methods [24]. After purification on a
cesium chloride (CsCl) density gradient, adenoviral stocks were immediately frozen as single
use aliquots in 10% glycerol at -80°C, and the infectivity of the stocks was determined using the
Adeno-X Rapid Titer kit (BD Clontech). The presence of the inserted transgene was validated
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in all the recombinant Ad5 vectors by sequence analysis prior to their use for vaccination in
mice. The genome of YF-17D virus with the position of the two known class I-restricted epi-
topes in B6 (H-2b) mice and the derived Ad-YF vectors, are depicted in Fig 1.
YF-17D virus preparation and quantitation
YF-17D virus (Stamaril, Sanofi Pasteur; reconstituted as recommended by the manufacturer)
was propagated in Vero (ATCC CCL-81) cells grown in DMEM containing 10% FCS, glutamine
and antibiotics (penicillin and streptomycin). Cell monolayers were seeded 24 hours earlier and
infected with at a multiplicity of infection (MOI) of 0.001/cell in DMEM 2% FCS; infectious
supernatants were harvested when cytopathic effect was more than 60% (day 6 p.i), freeze-
thawed and clarified of cell debris at 2000 rpm for 15 min at 4C°. Viral stocks were stored as sin-
gle use aliquots at -80C°. For determining virus infectious titers, we used an Immuno Focus assay
(IFA) recently developed in our lab [22]. In brief, virus stocks were serially diluted (ten-fold) in
DMEM and adsorbed for 1h at 37 C° onto Vero (ATCC CCL-81) cell monolayers in twenty
four-well plates; cells were then overlaid with media containing 0.9%methyl cellulose and incu-
bated at 37 C° for 3 days. Following fixation and permeabilization, a monoclonal antibody
directed against NS3 from YF-17D virus was used for detection of virus antigens within infected
cells; the foci of infection (analogous to plaques) were visualized using HRP-substrate reaction
and counted. When virus titers in the brains were determined, the IFA was performed on serial
10-fold dilutions of homogenized and clarified 10% organ suspensions.
Fig 1. Schematic representation of the YFV virus genome and of the recombinant adenoviral vectored-vaccines used in this study. Three vectors
encoding antigens from the YF-17D virus were used: Ad-YF C,M,E, Ad-YF NS3 and Ad-YF NS3(201–325). The positions of the two previously identified murine
MHC class I-restricted viral epitopes have been indicated.
doi:10.1371/journal.pntd.0004464.g001
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Plaque reduction neutralization test
Neutralizing antibodies to YF-17D virus in sera from vaccinated mice were measured as
described previously [22]. Briefly, appropriately diluted YF-17D virus (resulting in about 70–
100 pfu per well) was incubated for 1 hour at 37°C with serial (2-fold) dilutions of mouse sera
obtained from individual mice vaccinated with Ad-YF C,M,E or Ad-YF NS3. The virus-serum
mixture was subsequently added to Vero cells monolayers in 24-well plates and incubated for 2
hours at 37°C, after which the overlay media containing 0.9% methyl cellulose was added.
After 3 days of incubation at 37°C, the overlay media was removed and, following fixation and
permeabilization, cells were stained as described above (IFA). Following counting, the neutral-
izing antibody titer, defined as the highest serum dilution neutralizing more than 50% of the
viral plaques, was determined.
Vaccination and challenge
For adenovirus vaccination, 2x107 pfu of recombinant Ad-5 in a volume of 30 μl was given sub-
cutaneously to isofluorane-anesthetized mice in the right hind foot pad; vaccination with YF-
17D virus at the dose of 105 pfu in 300 μl was given subcutaneously (s.c.) at the base of the tail.
In YFV challenge studies, deeply anesthetized mice were injected intracranial with 104 pfu
of YF-17D virus in a volume of 30 μl; when assessing clinical protection, mice were checked
twice daily for two weeks following intracranial challenge and euthanized when development
of illness (drop in body weight, ruffled fur, twitching) together with neurologic signs (hind leg
paralysis and weakness) were observed. Mice developing sickness within 4 days post challenge
were excluded from experiments.
In vivo depletion of T cells
A combination of two monoclonal antibodies (YTS 169 and YTS 156)[25,26] was used for in
vivo depletion of CD8+ T cells from vaccinated mice prior to challenge. Mice to be depleted
were injected i.p. with 100 μg of antibody one day prior to i.c challenge and at days 1 and 4
post challenge. The efficiency of the depletion was confirmed by flow cytometric analysis at
day 7 post challenge.
Spleen cell preparation and flow cytometry
Single cell suspensions of splenocytes were obtained by pressing the organs through a fine steel
mesh (mesh size, 70 μm), followed by centrifugation and re-suspension in RPMI 1640 cell cul-
ture medium. The frequencies of antigen-specific CD8+ T cells in the spleen were determined
by intracellular cytokine staining (ICS) performed after 5 h of incubation with relevant pep-
tides (0.1 μg/ml of NS3 (268–275) or E (4–12)) in the presence of monensin (3 μM) at 37°C in 5%
CO2. After incubation, the cells were stained with Abs for cell surface markers (peridinin chlo-
rophyll protein-Cy5.5- or BrilliantViolet 421-CD8, APC-Cy7-CD44) and Ab for intracellular
cytokine (APC- interferon gamma [IFN-γ]). Samples were run on an LSRII flow cytometer
(BD biosciences) and analyzed using FlowJo software (TreeStar).
Statistical analysis
A nonparametric Mann-Whitney U test was used to compare quantitative data; survival after
viral challenge was analyzed using the Log Rank test (p< 0.05; p< 0.01; (p< 0.001).
GraphPad Prism (version 6) software was used for statistical analysis.
Adenovectored Vaccines Against Yellow Fever Virus
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Results
Ad-YF vectors targeting both structural and non-structural gene products
induce relevant antiviral immunity
As a first approach to evaluate our YF vaccine candidates, we analysed the immunogenicity of
our structurally and non-structurally targeted vectors (see Fig 1) in terms of their capacity to
induce effector CD8+ T cells and virus-specific antibodies in vaccinated mice. From previous
studies it is known that both vectors contained T-cell epitopes of relevance in H-2b mice: a
dominant H-2Kb-restricted epitope has been mapped to the NS3 protein, and an H-2Db-
restricted subdominant epitope can be found in the viral E protein [27]. Consequently, to eval-
uate the CD8+ T-cell responses elicited in vaccinated mice, wt B6 mice were inoculated in the f.
p. with 2x107 pfu of either of the two prototypic Ad5 vaccines, and the kinetics of the primary
CD8+ T-cell responses was followed by flow cytometric analysis of ICS; a group of mice vacci-
nated with 105 pfu of YF-17D virus s.c. was included for comparison. As can be seen in Fig 2A,
both constructs induced strong CD8+ T-cell responses against the YFV epitope encoded by the
vector in question. Furthermore, it should be noted that the magnitude of T-cell responses gen-
erated in adenovector vaccinated mice markedly surpassed those elicited by the YFV vaccine;
whether this is also the case in humans we do not know, but certainly adenobased vaccines are
highly immunogenic also in primates [12,13].
Besides CD8+ T-cell responses, we also measured the antibody responses induced in vacci-
nated mice by an in vitro neutralization assay. As can be seen in Fig 2B, the Ad-YF C,M,E vec-
tor expressing the surface antigens of the YFV induced a clear virus-neutralizing response,
albeit not quite at the level found subsequent to YF vaccination [22]. In contrast, mice vacci-
nated with the vector encoding NS3 did not generate any antibodies detectable in the neutrali-
zation assay. From these results we conclude that Ad-YF C,M,E induces both a humoral and a
cell-mediated immune response of potential relevance to in vivo protection, while Ad-YF NS3
induces only a relevant cell-mediated response.
Vaccination with both Ad-YF vectors confers protection against YF
intracranial challenge
Having determined the type and magnitude of immune responses elicited by each of our adeno-
viral vectors, we proceeded to test the protective efficacy of a single immunization with either of
the two Ad-YF vectors. Mice were inoculated with 2x107 pfu of Ad-YF C,M,E, Ad-YF NS3 or
PBS in the f.p., and 14 days later, all animals were intracranial challenged with 104 pfu of YF-17D
virus (Fig 3). The intracranial challenge model we adopted has previously been shown to induce
a uniformly fatal neurotropic disease in naïve B6 mice, while YFV vaccinated mice are protected
from disease [22]. We found that vaccination with Ad-YF C,M,E resulted in 100% protection
from viral challenge, while all sham-vaccinated (PBS) mice succumbed to the infection (Fig 2).
Interestingly, vaccination with Ad-YF NS3 resulted in 80% protection from subsequent YF chal-
lenge. Since this vector only encodes a non-structural viral protein, which is found exclusively in
infected host cells, and since we have previously demonstrated that NS3 specific CD8+ T cells
infiltrate the YF-infected brain [22], the latter observation strongly supported the idea that pro-
tection in this animal model of YFV infection may be accomplished by T cells alone.
Protection afforded by Ad-YF NS3 vaccination relies on CD8+ T-cell
responses
To confirm the hypothesis that T-cell immunity suffices for protection, we first evaluated the
outcome of YFV challenge in several mouse knock-out (KO) strains carrying targeted
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deficiencies in CD8+ T-cell responses or in their effector molecules. Thus, wt B6 mice, β2m KO
mice, H-2kb KO mice and IFN-γ/Prf double KO mice were vaccinated with Ad-YF NS3; 14
days later, the mice were intracranial challenged with 104 pfu of YF-17D virus, and the clinical
outcome was monitored. Additionally, MHC class II KO mice were included in the experiment
to examine the role of CD4+ T cells in the Ad-YF NS3 induced response.
Fig 2. Analysis of immune responses induced by vaccination with Ad-YF vectors.WT B6 mice were vaccinated with Ad-YF C,M,E, Ad-YF NS3 or YF-
17D virus. a) Numbers of CD44+IFN-γ+ CD8+ T cells following ex vivo peptide stimulation with NS3(268–275) and E(4–12) are depicted as a function of time after
vaccination; non-stimulated cells serve as controls; symbols denote individual animals. b) Neutralizing antibody titers as a function of time after vaccination.
The dashed line indicates the median titer of the neutralizing antibody measured in WT B6mice vaccinated with YF-17D virus (cf. ref. (21)); symbols denote
individual animals.
doi:10.1371/journal.pntd.0004464.g002
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As can be seen in Fig 4A, we found that NS3 induced protection was completely abrogated
in β2m KOmice (no survival), and profoundly impaired in H-2K
b KO mice, in which case only
10% of vaccinated animals survived the challenge, whereas the survival of wt B6 mice in this
experiment was 100%. Given that the H-2Kb molecule is the restriction element for the domi-
nant NS3(268–75) epitope [27], this result strongly support the idea that the CD8
+ T cells specific
for this epitope may be accountable for the vector-induced immunity; however, formally we
cannot rule out the contribution of additional H-2Kb-restricted epitopes potentially present in
the NS3 protein. Consistent with a dominant role for effector T cells, the combined deficiency
of IFN-γ and perforin also resulted in complete abrogation of protection, with no survivors
recorded among vaccinated IFN-γ/Prf double KO mice (Fig 4A). Thus, we concluded that the
Ad-YF NS3 vector induces immunity to YFV via IFN-γ and/or perforin producing CD8+ T
cells specific for viral H-2kb-restricted epitopes.
Notably, we also found that the absence of CD4+ T cells resulted in a total suppression of
protective immunity (no survival in MHC class II KO mice) (Fig 4A). This cannot reflect lack
of help to B cells, since the NS3 vaccine does not induce protective antibodies. However, a
requirement for CD4+ T cell help for an effective CD8+ T cell response to Ad5-encoded viral
antigens has previously been demonstrated [28]. Therefore, to test whether this was also the
case for NS3 from the YF-17D virus, MHC class II KO mice, as well as wt B6 mice, were
vaccinated with Ad-YF NS3, and the splenic CD8+ T cell response was analyzed by ICS at day
8 post vaccination. We found that MHC class II KO mice presented a significantly reduced
NS3 (268–75) specific CD8
+ T-cell response as evident by markedly lower numbers of IFN-γ pro-
ducing CD8+ splenocytes in these mice compared to wt B6 animals (Fig 4B). Taken together,
these findings imply that CD8+ T cells are the major effectors in the immune response induced
by Ad-YF NS3 vaccination, and that CD4+ T cell help is essential in the priming phase.
Whether CD4+ T cells are also important at later stages of the immune response cannot be
established from our data, but “helpless” CD8+ T cells are known to be inferior with regard to
survival and ability to undergo secondary expansion [29,30].
Fig 3. In vivo protection induced by vaccination with Ad-YF vectors.WT B6 mice were vaccinated with
Ad-YF C,M,E or Ad-YF NS3 and intracranial challenged with YF-17D virus. Survival of vaccinated mice are
compared to that of sham vaccinated (PBS) animals. N = 5 in all groups. Experiment performed twice with
similar results.
doi:10.1371/journal.pntd.0004464.g003
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Viral loads in the brains of mice vaccinated with Ad-YF NS3 vectors
match CD8+ T-cell activity
The fact that Ad-YF NS3 induced protection depends on cell-mediated immunity, suggested to
us that, upon intracranial challenge, the virus inoculum would have to be cleared from the
CNS of wt B6 mice by CD8+ effector T cells. As we had previously observed that lack of H-2Kb
molecule resulted in a very drastic reduction of the Ad-YF NS3 induced protection in vivo
(10% in H-2Kb KO mice vs. 100% in B6 mice), we wanted to confirm that NS3 vaccinated H-
2Kb deficient mice would not be able to control YF-17D infection of the CNS following intra-
cranial challenge. Finally, to further narrow down the identity of the involved T cells, we made
an adenoconstruct encoding a truncated version of NS3 (Ad-YF NS3 (201–325)), and the protec-
tion associated with this vector was compared to that of the full length NS3 vector. Thus, we
analyzed the viral loads in the brains of wt B6 mice that had been immunized with Ad-YF NS3
or Ad-YF NS3 (201–325) 14 days prior to intracranial YF challenge, as well as of H-2k
b KO mice
immunized with Ad-NS3 prior to intracranial challenge. Unvaccinated wt B6 mice served as
controls. Viral titers were analyzed 7 days post challenge as this represents the latest time point
for unbiased analysis of acutely challenged mice that would invariably succumb between day 8
and 9 p.c. As expected, the unvaccinated mice uniformly displayed a high viral burden in the
CNS (106−107 pfu/g of brain), while the infection appeared to be partly controlled in the brains
of Ad-YF NS3 immunized mice with viral titers about 3 logs lower than in the unvaccinated
controls (Fig 5). Interestingly, vaccination of wt B6 mice with the truncated version of NS3
(Ad-YF NS3 (201–325)) also resulted in a significantly reduced viral burden in the brain as com-
pared to unvaccinated mice (Fig 5), albeit not quite to the same degree as observed in full-
length vaccinated mice. Notably, NS3 immunized H-2Kb deficient mice all displayed high viral
loads in the CNS, almost at the same level as in unvaccinated mice. The same difference in the
capacity to control YFV infection was observed when wt and H-2kb deficient mice had been
vaccinated 60 days prior to challenge (see S1 Fig). These results confirmed that vaccination
Fig 4. Role of CD8+ T cells in mediating protection from YF viral challenge following Ad-YF NS3 vaccination.WTB6 mice, H-2Kb KOmice, β2m KO
mice, IFN-γ/Prf double KOmice and MHC class II KOmice were vaccinated with Ad-YF NS3 and 14 days later intracranial challenged with YF-17D virus. a)
Survival curves are depicted; n = 5 in WT group and 10 in all other groups. b) Numbers of NS3(268–275)—specific CD8
+ T cells in the spleen of WT B6 mice
and MHC class II KOmice 8 days post Ad-YF NS3 vaccination are enumerated. Results are pooled from two independent experiments; symbols denote
individual animals.
doi:10.1371/journal.pntd.0004464.g004
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with the Ad-YF NS3 vector could induce protection through CD8+ T cells predominantly spe-
cific for H-2Kb restricted epitopes. Furthermore, the finding that mice given Ad5 encoding the
truncated or the full length form of the NS3 protein displayed overlapping reductions in viral
loads corroborated the hypothesis that the NS3 (268–275) specific CD8
+ T cells represent a key
subset of CD8+ T cells pivotal in Ad-YF NS3-induced antiviral immunity, albeit additional epi-
topes may also play a minor role.
Protection induced by Ad-YF C,M,E relies on both T and B cell
responses
Our best Ad-YF vaccine candidate in terms of in vivo protection appeared to be the vector
encoding the viral structural proteins. Given that vaccination with this construct unlike the
NS3 targeted construct induced a significant humoral response, we hypothesized antibodies
were mainly responsible for the protection observed in Ad-YF C,M,E vaccinated mice. To test
this hypothesis, we compared the outcome of intracranial YF challenge in vaccinated B-cell KO
mice, H-2Kb/Db double KO mice and wt B6 mice. Mice were injected with 2x107 pfu of Ad-YF
C,M,E in the f.p. two weeks prior to intracranial challenge, and the clinical outcome was moni-
tored for 15 days after challenge. Interestingly, lack of B cells only resulted in diminished, but
not abrogated protection (about 43% survival, Fig 6), relicating what we have recently observed
Fig 5. Viral loads in the brains of mice vaccinated with Ad-YF NS3 or Ad-YF NS3 (201–325) reflect CD8
+ T
cell numbers.Non-vaccinated, Ad-YF NS3 vaccinated or Ad-YF NS3 (201–325) vaccinatedWT B6mice (filled
squares) as well as Ad-YF NS3 vaccinated H-2Kb KOmice (open squares) were challenged with YFV
intracranial 14 after vaccination, and viral titers in the CNS were determined 7 days later. Symbols denote
individual animals.
doi:10.1371/journal.pntd.0004464.g005
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regarding mice vaccinated with YF-17D [22]. In the case of MHC class I KO mice lacking both
H-2kb and H-2Db molecules and with no known defects in B cell/antibody responses, we
observed that protection was significantly reduced (40% survival) as compared to survival of all
immunized wt B6 mice (Fig 6). Taken together these data suggested that a combination of
CD8+ T-cell and B-cell responses are required for protection as induced by Ad-YF C,M,E, thus
completely mimicking the protective response in YF-17D vaccinated animals [22].
Protection in Ad-YF C,M,E vaccinated mice reflects a combination of
CD8 T-cell mediated and humoral immunity, while protection following
NS3 entirely relies on CD8+ T cells
Based on the above results it would appear that both humoral and T-cell mediated immunity
were involved in protecting Ad-YF C,M,E vaccinated mice, while only CD8+ T cells contrib-
uted significantly in Ad-YF NS3 vaccinated animals. However, as the above result were
obtained using KO mice and therefore could have been biased from events taking place during
the priming phase, we decided to reassert our interpretation by performing acute depletion of
CD8+ T cells prior to intracranial challenge of both Ad-YF C,M,E and Ad-YF NS3 vaccinated
wt mice. To this end, animals were vaccinated as previously described and intracranial chal-
lenged with YFV 60 days later; unvaccinated wt mice were included as controls. Part of the vac-
cinated mice were depleted of CD8+ T cells in connection to the challenge and on day 7 p.c.,
brains from all mice were collected and viral titers were determined. As expected (Fig 7A),
unvaccinated animals all exhibited high viral loads, while most Ad-YF C,M,E vaccinated mice
had completely cleared infectious virus from the CNS by day 7 p.c. In these mice CD8+ T-cell
depletion lead to a significantly increased viral load, but brain virus titers were still several logs
lower in these animals than in the unvaccinated controls; this matches what we recently
observed in YF-17D vaccinated mice [22]. In contrast, but still as expected, infectious virus was
detected in the CNS of Ad-YF NS3 vaccinated, CD8+ T-cell replete animals, but with viral
loads significantly lower than in unvaccinated controls, and antiviral protection was completely
abrogated following CD8+ T-cell depletion (Fig 7A).
Fig 6. Protection from lethal disease following vaccination with Ad-YF C,M,E relies on both T- and B-
cell responses.WT B6mice, B cell KO mice and H-2Kb/Db KOmice were vaccinated with Ad-YF C,M,E and
intracranial challenged 14 days later with YFV. Survival curves for each group of vaccinated KOmice are
compared to that of vaccinated WT B6mice. WT: n = 10; B cell KO: n = 7; H-2Kb/Db KO: n = 5. The depicted
data are pooled from two independent experiments.
doi:10.1371/journal.pntd.0004464.g006
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To define the precise effector mechanisms elaborated by NS3-specific CD8+ T cells, we next
analysed the virus titers in brains of Ad-YF NS3 vaccinated IFN-γ KO, Prf KO, IFN-γ/Prf double
KO as well as wild type mice that were intracranial challenged 14 days post vaccination; strain-
matched unvaccinated animals served as controls (Fig 7B). We observed that vaccination with
Ad-YF NS3 still induced a significant, but markedly reduced protection in the absence of IFN-γor
Prf. On the other hand, vaccinated double KOmice could not control YFV infection of the CNS
and displayed viral loads similar to those of strain matched unvaccinated control animals (Fig 7B)
confirming our earlier finding regarding survival of vaccinated double KOmice (Fig 4A).
A single vaccination with Ad-YF vectors elicit long-lasting protection
Finally we asked how long Ad vector-induced protection would last. To this end mice were vac-
cinated with each of the two adenoviral vectors as before, and 60 and 210 days later, the mice
were intracranial challenged with YFV; 7 days later viral loads in the CNS of vaccinated ani-
mals were compared to those in unvaccinated controls. As can be seen in Fig 8, markedly
reduced virus titers were found in both groups of vaccinated mice compared to unvaccinated
controls 60 days post vaccination, and, notably, we did not observe any tendency towards a
decline in vaccine-induced protection in the mice vaccinated 210 days earlier, indicating that
even when acting on their own, CD8+ T cells have the capacity to provide long-term clinical
protection in this murine model of YFV infection.
Discussion
The first generation of viral vaccines comprised empirically attenuated live viruses, which have
been documented to be very effective in preventing many infections. The yellow fever vaccine
(YF-17D) belongs to this category, and with more than 500 million doses administered
Fig 7. Protection in Ad-YF C,M,E vaccinatedmice reflects a combination of CD8 T-cell mediated and humoral immunity, while protection following
NS3 entirely relies on cytolytic and/or cytokine producing CD8+ T cells. a) WT B6 mice were vaccinated with Ad-YF C,M,E or Ad-YF NS3 and
intracranial challenged with YFV 60 days later; part of the vaccinated animals were in vivo depleted of CD8+ T cells (α-CD8) 1 day prior to intracranial
challenge, and again at days +1 and +4 after challenge. Viral titers in the CNS of Ad-YF vaccinated and Ad-YF vaccinated/CD8 depleted mice 7 days after
challenge are compared to those in unvaccinated control animals. Dots represent individual animals. b) IFN-γ KO, Prf KO, IFN-γ/Prf double KO andWT B6
mice were vaccinated in the f.p. with Ad-YF NS3 and, 14 days later, intracranial challenged with YF-17D virus; viral titers in the CNS of vaccinated mice are
compared to those of matched unvaccinated control animals at day 7 post YF challenge. Dots represent individual animals.
doi:10.1371/journal.pntd.0004464.g007
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worldwide in the past 70 years, it stands as a paradigm for an effective vaccine [1,5]. For a
number of years there was limited interest in further development of YF vaccines due to the
successful application of the live attenuated vaccine. In the last decade, however, the use of the
YF-17D virus has come into focus again due to the risk of serious adverse events following vac-
cination, and due to restrictions in immunizing certain categories, such as infants, pregnant
women, elderly and immune-compromised people [31]. This has created a demand for alterna-
tive vaccine candidates [31], but only a limited number of studies have so far come up with
potential new YF vaccines, and they have mostly been focused around making an inactivated
vaccine inducing humoral immunity [32–34]. However, if as suggested by both of our studies
[22], elicitation of an antiviral CD8 T-cell response is pivotal for full protection against YFV
infection, an inactivated vaccine would not represent the best choice, whereas an Ad-vector
based vaccine would seem an ideal solution. In a very recent study [11], a naked DNA vaccine
encoding the E protein was tested in a murine model similar to ours and found to protect
against a fatal outcome of intracranial infection; antibody levels were sufficient to explain the
prevention of any mortality, whereas numbers of virus-specific T cells were quite low com-
pared to what we obtain. Importantly, any functional importance of the induced T-cell
response was not documented.
In this report, we have evaluated two prototypic Ad-based vectors encoding different YF-
17D proteins. The choice of these proteins was based on our previous analysis of how the exist-
ing YFV vaccine works [22] and thus represents a translational approach to use the informa-
tion previously gathered directly in the early design of a safer, but still highly efficient vaccine
candidate. Our results clearly demonstrate that induction of YFV-specific CD8+ T-cell
responses can lead to effective antiviral immunity in an infection model where protection until
recently was ascribed entirely to neutralizing antibodies [4]. We demonstrate that a single
Fig 8. Single vaccination with either adenovector induces long-lasting protection in WTmice.WT B6
mice were vaccinated with Ad-YF C,M,E or Ad-YF NS3 and intracranial challenged with YFV 60 or 210 days
later. On day 7 post challenge viral loads in the CNS of vaccinated animals are compared to those in
unvaccinated control mice. Dots represent individual animals.
doi:10.1371/journal.pntd.0004464.g008
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vaccination with Ad-YF NS3, containing a conserved nonstructural viral protein, can induce
almost complete protection from subsequent intracranial YFV challenge in wt B6 mice, and
that CD8+ T cells specific for H-2Kb-restricted viral epitopes are the major effectors in the vac-
cine-induced immunity. These findings confirm and extend recent results obtained in similarly
challenged YF-17D vaccinated mice [22]. Here we obtained strong evidence for a primary role
of antibodies in the protection against YF disease in mice, but also found evidence pointing to
a supporting role for virus-specific CD8+ T cells. Thus, an accelerated influx of virus-specific
CD8+ T cells into the infected CNS was revealed in vaccinated mice, and CD8+ T-cell depletion
significantly reduced antiviral protection [22]. In the present study we observed that CD8+ T-
cell depletion completely abolished virus control in Ad-YF-NS3 vaccinated mice, and under
these conditions we could show that absence of either IFN-γ or perforin significantly impaired
virus control, whereas deficiency of both completely prevented a reduction in CNS viral load at
7 days post challenge. This is in slight contrast to our previous findings in YF-17D vaccinated
mice in which case only mice lacking both IFN-γ and perforin were found to be significantly
impaired in their ability to control infection of the CNS [22]. This apparent discrepancy proba-
bly reflects that YD-17D vaccinated mice unlike NS3 vaccinated mice have preexisting neutral-
izing antibodies, which also contribute to the observed virus control and hence lead to a
blurring of the results [22]. Thus taken together our data convincingly demonstrate that T-cell
released effector molecules together with antibodies represent an integrated component of the
adaptive immune response to YFV in CNS.
To further address whether this focused T-cell response could be responsible for the in vivo
protection conferred by Ad-YF NS3 vaccination, we designed a vector encoding a truncated
version of the protein (Ad-YF-NS3 (201–325)). In preliminary experiments we observed that
the truncated form of NS3 induced similar numbers of NS3 (268–275) specific T cells as did
the full length protein (average of 5 mice/group: 107 tetramer+ CD8 T cells/spleen in Ad-
YF-NS3 (201–325) vaccinated mice vs. 9x10
6 CD8 T cells/ spleen in Ad-YF NS3 vaccinated
mice). However, the immune mediated virus control in the CNS was slightly reduced in mice
vaccinated with the former construct, suggesting that while NS3 (268–275) specific T cells clearly
represent the functionally most important subset of CD8+ T cells in NS3 immunized mice,
there are likely to be additional minor specificities involved following immunization with the
full length construct.
Notably, our attempt of generating a vector encoding the three YF viral structural proteins
C, M and E resulted in an even more promising vaccine candidate. This was, to some extent,
expected, as neutralizing Abs directed against the E protein have long been associated with pro-
tection from yellow fever [4]. However, upon immunization with Ad-YF C,M,E, we also noted
a very strong CD8+ T cell response toward the subdominant viral epitope contained in the E
protein, as compared to vaccination with YF-17D virus. CD8 T-cell depletion of these mice
confirmed that antiviral protection reflected a combination of a humoral and a cell-mediated
immune response similar to what we have recently found to be the case in YFV vaccinated
mice [22]. Analysis of the neutralizing titers in Ad-YF C,M,E vaccinated mice revealed that
such antibodies were induced, albeit not quite to the same level as found in YFV vaccinated
mice.
In conclusion, our current results provide new independent support for our recent claim
[22] that CD8+ T cells may play a significant role as effector cells against YFV infection. Still,
the mechanisms of protection against intracranial challenge in mice may differ from those con-
trolling the liver infection of humans. T-cell mediated immunity may be particularly important
for controlling CNS infection owing to the blood/brain barrier, which initially limits antibody
access. Most importantly, however, our findings demonstrate that by using the information
previously gathered in studies of YFV vaccinated mice [22], it was possible to make promising
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vaccines candidates based on replication deficient adenoviral vectors, which might work—
either alone (Ad-YF C, M, E) or combined (to broadened the T-cell response)—as potentially
safe alternatives to the use of a live attenuated vaccine for induction of protection against YFV-
induced disease; certainly, SAEs which represent visceral and neural dissemination of the
attenuated YFV vaccine should be avoided. Notably, when it comes to human vaccinations
there may be a need to substitute Ad5 with another adenovector due a high prevalence of anti-
bodies against this serotype in certain human populations [35–37]. However, adenoviral vec-
tors of non-human origin have already reached clinical testing (Ebola [38]) and several appear
to match Ad5 in immunogenecity and safety [19,39]. Another critical issue may be the longev-
ity of adenovector-induced protection in humans, e.g. adenoinduced protection towards Ebola
infection is short-lived in non-human primates [18]. This should not represent a major prob-
lem, however, since numerous studies have demonstrated that adenovector priming works well
in conjunction with heterologous boosting, e.g. using modified vaccinia Ankara [18]. In sum-
mary, our findings are very promising, and we believe that an adenovector based approach to
develop a safer alternative for YFV vaccination deserves further evaluation in relevant animal
models.
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S1 Fig. WT B6 mice and H-2Kb KOmice were vaccinated with Ad-YF NS3 and intracranial
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